chlorothiazide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diuretics, chlorothiazide derivatives	609	58-94-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: chlorothiazide chlorothiazide sodium	A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) Molecular weight: 295.71 Formula: C7H6ClN3O4S2 CLOGP: -0.29 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 118.69 ALOGS: -2.85 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

chlorothiazide
chlorothiazide sodium

A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

Molecular weight: 295.71
Formula: C7H6ClN3O4S2
CLOGP: -0.29
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 118.69
ALOGS: -2.85
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	O
0.50	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	92 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	13 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	112.60 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	0.70 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Sept. 4, 1958	FDA	OAK PHARMS AKORN

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary vein stenosis	35.55	27.11	5	1081	83	63487853
Rhinovirus infection	33.91	27.11	9	1077	4520	63483416
Respiratory failure	30.71	27.11	20	1066	101838	63386098
Hypervolaemia	30.28	27.11	13	1073	28400	63459536
Hypoxia	29.13	27.11	16	1070	59776	63428160

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Respiratory failure	42.23	26.29	34	1292	108538	34847067
Hyperparathyroidism secondary	41.34	26.29	10	1316	1558	34954047
Pulmonary hypertension	35.99	26.29	17	1309	20907	34934698
Respiratory distress	32.67	26.29	19	1307	35646	34919959
Serotonin syndrome	27.68	26.29	14	1312	19919	34935686

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Respiratory distress	50.86	24.23	27	2176	58312	79683873
Respiratory failure	50.58	24.23	41	2162	180870	79561315
Hospitalisation	41.26	24.23	28	2175	94208	79647977
Hyperparathyroidism secondary	39.23	24.23	10	2193	2650	79739535
Pulmonary vein stenosis	37.11	24.23	6	2197	159	79742026
Hypoxia	36.68	24.23	27	2176	103216	79638969
Pulmonary hypertension	35.65	24.23	20	2183	48060	79694125
Pulmonary arterial hypertension	33.10	24.23	16	2187	28350	79713835
Rhinovirus infection	32.29	24.23	11	2192	7942	79734243
Hypervolaemia	29.60	24.23	17	2186	42673	79699512

Showing 1 to 10 of 13 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C03AA04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, THIAZIDES Thiazides, plain
ATC	C03AB04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, THIAZIDES Thiazides and potassium in combination
ATC	C03AH01	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, THIAZIDES Thiazides, combinations with psycholeptics and/or analgesics
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:35674	antihypertensive drugs
FDA CS	M0471776	Thiazides
FDA EPC	N0000175419	Thiazide Diuretic
FDA PE	N0000175359	Increased Diuresis
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents

Showing 1 to 10 of 14 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	indication	48447003
Edema	indication	267038008
Hypertensive urgency	indication	443482000
Edema due to Nephrotic Syndrome	indication
Edema due to Hepatic Cirrhosis	indication
Hypertension with Left Ventricular Hypertrophy	indication
Pulmonary Edema due to Chronic Heart Failure	indication
Peripheral Edema due to Chronic Heart Failure	indication
Nephrogenic diabetes insipidus	off-label use	111395007	DOID:12387

Showing 1 to 10 of 127 entries

Previous1 2 3 4 5…13Next

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Congestive heart failure	Indication
Dogs	Renal edema	Indication

🐶 Veterinary products

Show entries

Search:

Product	Applicant	Ingredients
Diuril	Boehringer lngelheim Animal Health USA Inc.	1
Diuril Tablet	Boehringer lngelheim Animal Health USA Inc.	1

Showing 1 to 2 of 2 entries

Previous1Next

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.53	acidic
pKa2	9.74	acidic
pKa3	4.58	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Solute carrier family 12 member 3	Transporter	P55017	S12A3_HUMAN	INHIBITOR	A2	5.43		WOMBAT-PK	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN					WOMBAT-PK

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
002292	NDDF
002293	NDDF
169210	MMSL
2396	RXNORM
2720	PUBCHEM_CID
372782002	SNOMEDCT_US
3950	MMSL
4017731	VUID
4017731	VANDF
4017732	VANDF

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Chlorothiazide	Human Prescription Drug Label	1	63323-658	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Chlorothiazide	Human Prescription Drug Label	1	63323-658	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Chlorothiazide	Human Prescription Drug Label	1	63323-658	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Chlorothiazide	Human Prescription Drug Label	1	63323-658	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Chlorothiazide	Human Prescription Drug Label	1	63323-658	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Chlorothiazide	Human Prescription Drug Label	1	63323-658	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Chlorothiazide Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1820	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
Chlorothiazide Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	17478-419	INJECTION	500 mg	INTRAVENOUS	NDA authorized generic	25 sections
Chlorothiazide Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	17478-419	INJECTION	500 mg	INTRAVENOUS	NDA authorized generic	25 sections
chlorothiazide sodium	HUMAN PRESCRIPTION DRUG LABEL	1	25021-305	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections

Showing 1 to 10 of 17 entries

Previous1 2Next